Publications

Export 4 results:
Author [ Title(Asc)] Type Year
Filters: Author is Feldman, Howard H  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
P
Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, Bakardjian H, Benali H, Bertram L, Blennow K et al..  2016.  Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.. Alzheimers Dement. 12(3):292-323.
E
Gauthier S, Feldman HH, Schneider LS, Wilcock GK, Frisoni GB, Hardlund JH, Moebius HJ, Bentham P, Kook KA, Wischik DJ et al..  2016.  Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial.. Lancet. 388(10062):2873-2884.
C
Chertkow H, Borrie M, Whitehead V, Black SE, Feldman HH, Gauthier S, Hogan DB, Masellis M, McGilton K, Rockwood K et al..  2019.  The Comprehensive Assessment of Neurodegeneration and Dementia: Canadian Cohort Study.. Can J Neurol Sci. 46(5):499-511.
A
Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JLuis, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R et al..  2014.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.. Lancet Neurol. 13(6):614-29.